# Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital

Study · id `cardio:ct-nct07250763` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07250763](<https://clinicaltrials.gov/study/NCT07250763>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07250763

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 145 participants.

## Technical summary

Registry record NCT07250763. Allocation not applicable; no masking; primary purpose treatment. Start 2023-09-20 (actual); primary completion 2027-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 145 participants (planned count; ClinicalTrials.gov record NCT07250763, source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)
- Started: 2023-09-20 (actual) (ClinicalTrials.gov record NCT07250763, source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)
- Primary completion: 2027-02-28 (anticipated) (ClinicalTrials.gov record NCT07250763, source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)
- Completion: 2027-05-31 (anticipated) (ClinicalTrials.gov record NCT07250763, source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07250763, source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07250763-2025-11-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
- Condition: Pulmonary Embolism
- Condition: Deep Vein Thrombosis
- Condition: Atrial Fibrillation
- Condition: Acute Cardiac Syndrome
- Condition: Mechanical Heart Valve Recipients
- Intervention (Drug): Initial Heparin Dose Modification
- Lead sponsor: Inova Health Care Services
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Inova Health Care Services (`cardio:org-inova-health-care-services`)

## Provenance

Content hash: 44a17c564b35b26ef06545fcf47f16b8d59206c88b2153a12fe935cb4eb54605
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
